MPD: List measures where strain KK/HlJ is an outlier

List measures where KK/HlJ is an outlier

Click on pulldowns below to see KK/HlJ means with summary statistic tooltips.
Within each pulldown, the "up" and "down" triangles indicate when this strain is an outlier.
You can also download all phenotypes for this strain and sort by Z score in Excel.

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Berndt1:10	Berndt1	ventilator	methacholine	airway resistance (H₂O pressure) [cm/mL/s] airway_res_series 34210 baseline MCh challenge (mg/mL): 1 3 10 30	inbred	37	both	9-12wks	N=8	2010

Berndt1:21	Berndt1	ventilator	methacholine	airway resistance (as % of baseline, H₂O pressure) [%] pct_res 34221 MCh challenge (mg/mL): 1 3 10 30	inbred	37	both	9-12wks	N=8	2010

Berndt2:61	Berndt2	plethysmography	methacholine	enhanced pause penh 35161 saline 5 MCh 10 MCh 20 MCh response index	inbred	29	both	9-12wks	N=8	2010

Berndt2:81	Berndt2	ventilator	methacholine	airway resistance (H₂0 pressure) [cm/mL/s] airway_res 35181 saline 1 MCh 3 MCh 10 MCh 30 MCh response index	inbred	29	both	9-12wks	N=9	2010

CGDpheno1:20	CGDpheno1	complete blood count	(none)	platelet count (PLT; units per volume x 10³) [n/µL] PLT 31820	inbred w/CC8	72	both	11wks	N=7	2009

CGDpheno1:21	CGDpheno1	complete blood count	(none)	mean platelet volume (MPV) [fL] MPV 31821	inbred w/CC8	72	both	11wks	N=7	2009

CGDpheno1:41	CGDpheno1	lipid profile	(none)	total cholesterol (plasma CHOL) [mg/dL] CHOL 31841	inbred w/CC8	72	both	12wks	N=7	2009

CGDpheno1:42	CGDpheno1	lipid profile	(none)	HDL cholesterol (plasma HDL) [mg/dL] HDLD 31842	inbred w/CC8	72	both	12wks	N=7	2009

CGDpheno1:50	CGDpheno1	metabolic panel	(none)	glucose (plasma GLU, 4h fast) [mg/dL] GLU 31850	inbred w/CC8	72	both	12wks	N=7	2009

CGDpheno1:80	CGDpheno1	DXA	(none)	whole body bone mineral density (BMD) [g/cm²] BMD 31880	inbred w/CC7	71	both	13wks	N=7	2009

CGDpheno1:87	CGDpheno1	DXA	(none)	percent fat, head excluded [%] pctFat 31887	inbred w/CC7	71	both	13wks	N=7	2009

Chen1:4	Chen1	immune cell quantification	(none)	percentage of invariant NK T cells that express CD4, spleen [%] pct_iNKT_CD4_spleen 52304	inbred	35	m	8-10wks	N=4	2011

Crowley1:7	Crowley1	inclined screen test	haloperidol	latency to move four paws, extrapyramidal side effects [s] latency 39407 day: 0 3 7 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

DiPetrillo1:1	DiPetrillo1	urinalysis	(none)	microalbumin (urine MA) [mg/dL] MA 46001	inbred w/CC7	34	m	10wks	N=13	2012

DiPetrillo1:3	DiPetrillo1	urinalysis	(none)	albumin-creatinine ratio (urine ACR) [mg/g] ACR 46003	inbred w/CC7	34	m	10wks	N=13	2012

Harrill1:46	Harrill1	histopathology	isoniazid	hepatocytic cytoplasmic, microvesiculation, multifocal [score] microvesic_multi 39546 control isoniazid	inbred	34	f	8-10wks	N=4	2011

Harrill2:5	Harrill2	body weight	DB289	fold change in body weight over testing period [ratio] bw_change 44105 control DB289 difference	inbred	34	f	6-8wks	N=5	2012

Harrill2:25	Harrill2	urinalysis	DB289	urine volume [mL] urine_vol 44125 control DB289 difference	inbred	33	f	6-8wks	N=5	2012

Harrill2:35	Harrill2	biomarker quantification	DB289	urine kidney injury molecule 1 (KIM-1) [pg] urine_KIM1 44135 control DB289 difference	inbred	33	f	6-8wks	N=4	2012

Haston1:3	Haston1	bronchoalveolar lavage assessment	radiation	percentage of macrophages in bronchoalveolar lavage [%] BAL_mac 48803	inbred	26	both	15-36wks	N=6	2012

HMDPpheno2:1	HMDPpheno2	lipid profile	(none)	HDL cholesterol (plasma HDL) [mg/dL] HDL 46401	HMDP w/par	99	m	16wks	N=7	2010

HMDPpheno2:3	HMDPpheno2	lipid profile	(none)	unesterified cholesterol (plasma CHOL) [mg/dL] CHOL_un 46403	HMDP w/par	99	m	16wks	N=7	2010

HMDPpheno2:4	HMDPpheno2	lipid profile	(none)	total cholesterol (plasma CHOL) [mg/dL] CHOL_tot 46404	HMDP w/par	99	m	16wks	N=7	2010

HMDPpheno2:6	HMDPpheno2	lipid profile	(none)	triglycerides (plasma TG, 16h fast) [mg/dL] TG 46406	HMDP w/par	99	m	16wks	N=7	2010

Korstanje1:1	Korstanje1	urinalysis	(none)	microalbumin (urine MA) [mg/dL] MA 29701 12mo 18mo 24mo	inbred	30	both		N=7	2008

Korstanje1:21	Korstanje1	urinalysis	(none)	albumin-creatinine ratio (urine ACR) [mg/g] ACR 29721 12mo 18mo 24mo	inbred	30	both		N=7	2008

Kumar3:27	Kumar3	open field test	(none)	duration of grooming events first 5 min (s per event) [s/n] GrBoutLength5m 112935	inbred w/CC8	62	both	8-14wks	N=15	2021

Kumar4:6	Kumar4	gait analysis	(none)	angular velocity over duration of stride, median [deg/s] angular_velocity_median 114436	inbred w/CC8	62	both	10-20wks	N=19	2021

Kumar4:7	Kumar4	gait analysis	(none)	angular velocity over duration of stride, variance [deg/s] angular_velocity_var 114437	inbred w/CC8	62	both	10-20wks	N=19	2021

Kumar4:17	Kumar4	gait analysis	(none)	base tail keypoint speed, mean [cm/s] speed_mean 114447	inbred w/CC8	62	both	10-20wks	N=19	2021

Kumar4:18	Kumar4	gait analysis	(none)	base tail keypoint speed, median [cm/s] speed_median 114448	inbred w/CC8	62	both	10-20wks	N=19	2021

Kumar4:19	Kumar4	gait analysis	(none)	base tail keypoint speed, variance [cm/s] speed_var 114449	inbred w/CC8	62	both	10-20wks	N=19	2021

Maurer1:5	Maurer1	ECG	atenolol, isoproterenol	heart rate [n/min] HR 33205 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:99	Maurer1	colony observation	(none)	age at testing (local parameter) [wks] age 33299	inbred	23	m		N=42	2009

Mills1:31	Mills1	chromosome instability assessment	(none)	red blood cells (RBC) with micronuclei [%] RBC_micronucl 25231 6mo 12mo 20mo	inbred	30	both		N=5	2008

Mills1:35	Mills1	chromosome instability assessment	(none)	non-nucleated peripheral blood cells with micronuclei [%] all_micronucl 25235 6mo 12mo 20mo	inbred	30	both		N=5	2008

Naggert1:2	Naggert1	metabolic panel	high-fat diet	glucose (plasma GLU, 4h fast) [mg/dL] GLU 14302 baseline after 17wks on diet Δchange	inbred w/CC7	43	both	7-9wks	N=10	2003

Naggert1:5	Naggert1	hormone quantification	high-fat diet	insulin [ng/mL] INS_fat18 14305	inbred w/CC7	43	both	25-27wks	N=12	2003

Naggert1:6	Naggert1	hormone quantification	high-fat diet	leptin [pg/mL] LEP_fat18 14306	inbred w/CC7	43	both	25-27wks	N=11	2003

Naggert1:17	Naggert1	DXA	high-fat diet	weight of fat portion of tissue mass, head excluded [g] fatwt_fat8 14317	inbred w/CC7	41	both	15-17wks	N=10	2003

Naggert1:19	Naggert1	DXA	high-fat diet	percentage of tissue mass that is fat, head excluded [%] pctfat_fat8 14319	inbred w/CC7	41	both	15-17wks	N=10	2003

Paigen1:5	Paigen1	body weight	high-fat diet	body weight [g] bw 2905 start after 8wks on diet fold change	inbred	43	both	7-11wks	N=12	2000

Paigen1:25	Paigen1	metabolic panel	high-fat diet	bile salts (plasma) [µmol/L] bilesalts 2925	inbred	43	both	15-19wks	N=8	2000

Paigen1:31	Paigen1	histopathology	high-fat diet	liver macrovacuoles (score: 0-4) [score] macrovacs 2931	inbred	43	both	15-19wks	N=3	2000

Paigen2:5	Paigen2	lipid profile	high-fat diet	non-HDL cholesterol (plasma) [mg/dL] nonHDL 9905 baseline after 17wks on diet Δchange	inbred w/CC7	42	both	7-9wks	N=9	2002

Paigen2:6	Paigen2	lipid profile	high-fat diet	total cholesterol (plasma) [mg/dL] CHOL 9906 baseline after 17wks on diet Δchange	inbred w/CC7	42	both	7-9wks	N=9	2002

Paigen2:21	Paigen2	lipid profile	high-fat diet	triglycerides (plasma, 4h fast) [mg/dL] TG 9921 baseline after 17wks on diet Δchange	inbred w/CC7	42	both	7-9wks	N=9	2002

Paigen4:1	Paigen4	lipid profile	(none)	HDL cholesterol (plasma) [mg/dL] HDLC 19701	inbred w/CC7	43	both	10wks	N=12	2002

Paigen4:2	Paigen4	lipid profile	(none)	total cholesterol (plasma) [mg/dL] CHOL 19702	inbred w/CC7	43	both	10wks	N=12	2002

Peters1:7	Peters1	complete blood count	(none)	mean RBC corpuscular hemoglobin concentration (MCHC) [g/dL] MCHC 6207	inbred w/CC7	43	both	10wks	N=12	2001

Peters1:11	Peters1	complete blood count	(none)	neutrophil differential (percent of total WBC) [%] NEUT 6211	inbred w/CC7	43	both	10wks	N=12	2001

Peters1:12	Peters1	complete blood count	(none)	lymphocyte differential (percent of total WBC) [%] LYM 6212	inbred w/CC7	43	both	10wks	N=12	2001

Peters1:19	Peters1	complete blood count	(none)	platelet count (PLT; units per volume x 10³) [n/µL] PLT 6219	inbred w/CC7	43	both	10wks	N=12	2001

Peters1:27	Peters1	coagulation test	(none)	partial thromboplastin time (PTT) [s] PTT 6227	inbred w/CC7	43	both	10wks	N=10	2001

Peters4:9	Peters4	complete blood count	(none)	neutrophil count (NEUT; units per volume x 10³) [n/µL] NEUT 24309 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:33	Peters4	complete blood count	(none)	neutrophil differential (NEUT; percentage of total WBC) [%] pctNEUT 24333 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:69	Peters4	complete blood count	(none)	mean RBC hemoglobin concentration (MCHC) [g/dL] MCHC 24369 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:89	Peters4	complete blood count	(none)	mean platelet volume (MPV) [fL] MPV 24389 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:93	Peters4	complete blood count	(none)	platelet count (PLT; units per volume x 10³) [n/µL] Plt 24393 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Petkova1:6	Petkova1	immune cell quantification	(none)	lymphocyte differential (LYM; percentage of total WBC) [%] LYM 24206 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:11	Petkova1	immune cell quantification	(none)	neutrophil differential (NEUT; percentage of total WBC) [%] NEUT 24211 6mo 12mo 18mo 24mo	inbred	32	both		N=7	2007

Petkova1:16	Petkova1	immune cell quantification	(none)	eosinophil differential (EOS; percentage of total WBC) [%] EOS 24216 6mo 12mo 18mo 24mo	inbred	32	both		N=7	2007

Petkova1:51	Petkova1	immune cell quantification	(none)	CD8 T cells, as percentage of total lymphocytes [%] CD8_all 24251 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Project1022:21	Project1022	None	(none)	Results Results 111124 12M 20M 6M LONG	inbred	31	both		N=12	2008

Project1032:63	Project1032	operant conditioning chamber	cocaine	number of active lever presses (during infusions and timeouts) (intravenous self administration), cocaine [n] active_cocaine 111476 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day 9 day 10	HMDP	66	both	9-15wks	N=2	2020

Project1032:89	Project1032	operant conditioning chamber	cocaine	number of inactive lever presses (intravenous self administration), cocaine [n] inactive_cocaine 111502 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day 9 day 10	HMDP	66	both	9-15wks	N=2	2020

Project1032:102	Project1032	operant conditioning chamber	cocaine	number of inactive lever presses (intravenous self administration) combined, cocaine [n] inactive_combined_cocaine 111515 days 1-4 days 5-7 days 8-10	HMDP	66	both	9-15wks	N=2	2020

Project1218:17	Project1218	None	(none)	BW BW 131955 LONG M12 M20 M6	other	31	both		N=9	2024

Reed1:3	Reed1	body size and weight	(none)	body weight [g] bw 32603	inbred	28	m	29-67wks	N=12	2009

Reed1:20	Reed1	body size and weight	(none)	body mass index (BMI) [kg/m²] bmi 32620	inbred	28	m	29-67wks	N=12	2009

Rusyn2:21	Rusyn2	metabolic panel	(none)	aspartate transaminase (serum AST), naive [IU/L] AST 36121	inbred	15	m	7wks	N=3	2010

Rusyn2:27	Rusyn2	metabolic panel	trichloroethylene	aspartate transaminase (serum AST), treated group [IU/L] AST_tce 36127 time: 2h 8h 24h	inbred	16	m	7wks	N=3	2010

Rusyn5:1	Rusyn5	metabolic panel	high-fat diet and ethanol	serum alanine transaminase (ALT) [IU/L] ALT 43001 high-fat only high-fat and ethanol	inbred	14	m	8-14wks	N=3	2011

Rusyn5:9	Rusyn5	alcohol quantification	high-fat diet and ethanol	urine alcohol concentration (UAC), daily peak [mg/dL] peak_UAC 43009 high-fat only high-fat and ethanol	inbred	14	m	8-14wks	N=3	2011

Rusyn5:13	Rusyn5	histopathology	high-fat diet and ethanol	liver steatosis (0-4) [score] steatosis 43013 high-fat only high-fat and ethanol	inbred	14	m	8-14wks	N=3	2011

Rusyn5:17	Rusyn5	histopathology	high-fat diet and ethanol	liver necrosis (0-2) [score] necrosis 43017 high-fat only high-fat and ethanol	inbred	14	m	8-14wks	N=3	2011

Rusyn5:19	Rusyn5	histopathology	high-fat diet and ethanol	total liver histopathology (0-8) [score] total_pathology 43019 high-fat only high-fat and ethanol	inbred	14	m	8-14wks	N=3	2011

Tordoff1:2	Tordoff1	body weight	(none)	average body weight during NaCl test (local parameter) [g] NaCl_bwavg 6102	inbred	28	m	4-12wks	N=12	2001

Tordoff1:8	Tordoff1	body weight	(none)	average body weight during KCl test (local parameter) [g] KCl_bwavg 6108	inbred	28	m	4-12wks	N=12	2001

Tordoff1:15	Tordoff1	body weight	(none)	average body weight during CaCl2 test (local parameter) [g] CaCl2_bwavg 6115	inbred	28	m	4-12wks	N=12	2001

Tordoff1:21	Tordoff1	body weight	(none)	average body weight during NH4Cl test (local parameter) [g] NH4Cl_bwavg 6121	inbred	28	m	4-12wks	N=12	2001

Tordoff2:8	Tordoff2	body weight	(none)	body weight average [g] bwavg 6308	inbred	28	m	4-12wks	N=12	2001

Tordoff3:4	Tordoff3	colony observation	(none)	age at the start of the 1st test (water) (local parameter) [d] age 10304	inbred w/CC7	40	both		N=10	2002

Tordoff3:5	Tordoff3	body weight	(none)	body weight [g] bw 10305 start end fold change	inbred w/CC7	40	both	8-10wks	N=10	2002

Tordoff3:25	Tordoff3	colony observation	(none)	age of mouse at death (local parameter) [d] age_end 10325	inbred w/CC7	40	both		N=10	2002

Tordoff3:26	Tordoff3	DXA	(none)	bone mineral density (BMD) [g/cm²] BMD 10326	inbred w/CC7	40	both	14-18wks	N=10	2002

Tordoff3:28	Tordoff3	DXA	(none)	weight of lean tissue, head excluded [g] lean_wt 10328	inbred w/CC7	40	both	14-18wks	N=10	2002

Tordoff3:29	Tordoff3	DXA	(none)	weight of fat tissue, head excluded [g] fat_wt 10329	inbred w/CC7	40	both	14-18wks	N=10	2002

Tordoff3:30	Tordoff3	DXA	(none)	total weight (lean + fat), head excluded [g] total_wt 10330	inbred w/CC7	40	both	14-18wks	N=10	2002

Tordoff3:31	Tordoff3	DXA	(none)	percent fat, head excluded [%] pct_fat 10331	inbred w/CC7	40	both	14-18wks	N=10	2002

Tordoff3:32	Tordoff3	DXA	(none)	percent lean, head excluded [%] pct_lean 10332	inbred w/CC7	40	both	14-18wks	N=10	2002

Wiltshire4:7	Wiltshire4	immune cell quantification	BEZ235	T cells, percent viability [%] Tcells_BEZ 52407 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:33	Wiltshire4	immune cell quantification	doxorubicin	monocytes, percent viability [%] monocytes_Dox 52433 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:47	Wiltshire4	immune cell quantification	idarubicin	T cells, percent viability [%] Tcells_Ida 52447 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:53	Wiltshire4	immune cell quantification	idarubicin	monocytes, percent viability [%] monocytes_Ida 52453 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Yuan3:11	Yuan3	metabolic panel	(none)	alkaline phosphatase (serum ALP) [IU/L] ALP 24411 6mo 12mo 18mo	inbred	32	both		N=7	2008

Yuan3:16	Yuan3	metabolic panel	(none)	calcium (serum Ca) [mg/dL] Ca 24416 6mo 12mo 18mo	inbred	32	both		N=7	2008

Yuan3:26	Yuan3	metabolic panel	(none)	iron (serum Fe) [mmol/L] Fe 24426 6mo 12mo 18mo	inbred	32	both		N=7	2008

Yuan3:66	Yuan3	metabolic panel	(none)	bilirubin (serum TBIL) [µmol/L] TBIL 24466 6mo 12mo 18mo	inbred	32	both		N=7	2008

List measures where KK/HlJ is an outlier

Filter Table Results